Direct susceptibility testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 system

Simple item page
dc.contributor.authorDemers, Anne-Marieen_ZA
dc.contributor.authorVenter, Amouren_ZA
dc.contributor.authorFriedrich, Sven O.en_ZA
dc.contributor.authorRojas-Ponce, Gabrielen_ZA
dc.contributor.authorMapamba, Danielen_ZA
dc.contributor.authorJugheli, Levanen_ZA
dc.contributor.authorSasamalo, Mohammeden_ZA
dc.contributor.authorAlmeida, Deepaken_ZA
dc.contributor.authorDorasamy, Aftonen_ZA
dc.contributor.authorJentsch, Uteen_ZA
dc.contributor.authorGibson, Maraen_ZA
dc.contributor.authorEveritt, Danielen_ZA
dc.contributor.authorEisenach, Kathleen D.en_ZA
dc.contributor.authorDiacon, Andreas H.en_ZA
dc.date.accessioned2018-09-13T10:26:10Z
dc.date.available2018-09-13T10:26:10Z
dc.date.issued2016-05
dc.descriptionCITATION: Demers, A.-M. et al. 2016. Direct susceptibility testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 system. Journal of Clinical Microbiology, 54(5):1276 –1281, doi:10.1128/JCM.03162-15.
dc.descriptionThe original publication is available at https://jcm.asm.org
dc.description.abstractPyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in >50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance to new drugs in experimental regimens.en_ZA
dc.description.sponsorshipGlobal Alliance for TB Drug Development
dc.description.urihttps://jcm.asm.org/content/54/5/1276
dc.description.versionPublisher's version
dc.format.extent6 pages
dc.identifier.citationDemers, A.-M. et al. 2016. Direct susceptibility testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 system. Journal of Clinical Microbiology, 54(5):1276 –1281, doi:10.1128/JCM.03162-15.
dc.identifier.issn1098-660X (online)
dc.identifier.issn0095-1137 (print)
dc.identifier.otherdoi:10.1128/JCM.03162-15
dc.identifier.urihttp://hdl.handle.net/10019.1/104424
dc.language.isoen_ZAen_ZA
dc.publisherAmerican Society for Microbiology
dc.rights.holderAuthors retain copyright
dc.subjectTuberculosis -- Treatmenten_ZA
dc.subjectPyrazinamideen_ZA
dc.titleDirect susceptibility testing of Mycobacterium tuberculosis for Pyrazinamide by Use of the Bactec MGIT 960 systemen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
demers_direct_2016.pdf
Size:
362.22 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.95 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Molecular Biology and Human Genetics)